125 related articles for article (PubMed ID: 38219332)
1. The impact of prognostic factors and comorbidities on survival in older adults with stage I - III cutaneous melanoma in Southwest Finland: A register study.
Mattila KE; Vihinen H; Heervä E; Nuotio MS; Vihinen P
J Geriatr Oncol; 2024 Mar; 15(2):101701. PubMed ID: 38219332
[TBL] [Abstract][Full Text] [Related]
2. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 May; 51(6):873-878. PubMed ID: 33758939
[TBL] [Abstract][Full Text] [Related]
3. Localized melanoma in older patients, the impact of increasing age and comorbid medical conditions.
Rees MJ; Liao H; Spillane J; Speakman D; McCormack C; Donahoe S; Pohl M; Webb A; Gyorki D; Henderson MA
Eur J Surg Oncol; 2016 Sep; 42(9):1359-66. PubMed ID: 26899940
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma.
Paver EC; Ahmed T; Burke H; Saw RPM; Stretch JR; Spillane AJ; Shannon KF; Vergara IA; Elder DE; Lo SN; Thompson JF; Scolyer RA
JAMA Dermatol; 2023 Dec; 159(12):1359-1367. PubMed ID: 37910123
[TBL] [Abstract][Full Text] [Related]
5. Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma.
El Sharouni MA; Aivazian K; Witkamp AJ; Sigurdsson V; van Gils CH; Scolyer RA; Thompson JF; van Diest PJ; Lo SN
JAMA Dermatol; 2021 Feb; 157(2):166-173. PubMed ID: 33355600
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of acral lentiginous histologic type in T1 melanoma.
Mejbel HA; Torres-Cabala CA; Milton DR; Ivan D; Feldmeyer L; Namikawa K; Nagarajan P; Tetzlaff MT; Curry JL; Ross MI; Hwu WJ; Prieto VG; Aung PP
Mod Pathol; 2021 Mar; 34(3):572-583. PubMed ID: 32759976
[TBL] [Abstract][Full Text] [Related]
7. Smoking is an Independent Marker of Poor Prognosis in Cutaneous Melanoma.
Mattila K; Vihinen H; Karlsson A; Minn H; Vihinen P; Heervä E
Acta Derm Venereol; 2023 Feb; 103():adv00860. PubMed ID: 36748330
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
Patuzzo R; Mattavelli I; Gallino G; Galeone C; Valeri B; Mocellin S; Del Fiore P; Ribero S; Mandalà M; Tauceri F; Lombardo M; Maurichi A;
Cancer; 2023 Aug; 129(15):2331-2340. PubMed ID: 37162404
[TBL] [Abstract][Full Text] [Related]
9. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
Tas F; Erturk K
Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
11. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
Stassen RC; Maas CCHM; van der Veldt AAM; Lo SN; Saw RPM; Varey AHR; Scolyer RA; Long GV; Thompson JF; Rutkowski P; Keilholz U; van Akkooi ACJ; Verhoef C; van Klaveren D; Grünhagen DJ
Lancet Oncol; 2024 Apr; 25(4):509-517. PubMed ID: 38547894
[TBL] [Abstract][Full Text] [Related]
13. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
14. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
16. Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 Feb; 51(2):192-198. PubMed ID: 33159197
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI).
Portelli F; Galli F; Cattaneo L; Cossa M; De Giorgi V; Forte G; Fraternali Orcioni G; Gianatti A; Indini A; Labianca A; Maurichi A; Merelli B; Montesco MC; Occelli M; Patuzzo R; Piazzalunga D; Pigozzo J; Quaglino P; Ribero S; Salvatori R; Saraggi D; Sena P; Senetta R; Valeri B; Tanaka M; Fukayama M; Palmieri G; Mandalà M; Massi D;
Br J Dermatol; 2021 Feb; 184(2):281-288. PubMed ID: 32282932
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.
Kyrgidis A; Tzellos T; Mocellin S; Apalla Z; Lallas A; Pilati P; Stratigos A
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010307. PubMed ID: 25978975
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in young women with cutaneous melanoma.
Burton AL; Egger ME; Quillo AR; Stromberg AJ; Hagendoorn L; Scoggins CR; Martin RC; McMasters KM; Callender GG
Am J Surg; 2014 Jan; 207(1):102-8. PubMed ID: 24330977
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences.
Ferhatoglu F; Erturk K; Faruk T
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
